CompletedPhase 1NCT06805487
Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge
Studying Zika virus disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Anna Durbin, M.D.Johns Hopkins Bloomberg School of Public Health
- Intervention
- TetraVax-DV-TV003 (TV003)(biological)
- Enrollment
- 27 enrolled
- Eligibility
- 18-40 years · All sexes
- Timeline
- 2024 – 2025
Study locations (2)
- Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States
- Center for Immunization Research, Baltimore, Maryland, United States
Collaborators
Johns Hopkins Bloomberg School of Public Health
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06805487 on ClinicalTrials.govOther trials for Zika virus disease
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT04398901Neurodevelopmental Outcomes in ZIKV-Exposed ChildrenChildren's National Research Institute
- ACTIVE NOT RECRUITINGPHASE3NCT03037164INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsCerus Corporation
- RECRUITINGNCT01386424Screening for LID Clinical Studies Unit Healthy Volunteer ProtocolsNational Institute of Allergy and Infectious Diseases (NIAID)